A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2014
At a glance
- Drugs MK 2637 (Primary) ; Dextromethorphan
- Indications Schizophrenia
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 24 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record